抗中性粒细胞胞外诱捕网（NETs）抗体增强抗双链 DNA 抗体在系统性红斑狼疮中的临床效能。

Antibodies against neutrophil extracellular traps (NETs) potentiate clinical performance of anti-double-stranded DNA antibodies in systemic lupus erythematosus.

机构信息

The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China; Department of Clinical Laboratory, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China; Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.

Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.

出版信息

Clin Immunol. 2023 Apr;249:109297. doi: 10.1016/j.clim.2023.109297. Epub 2023 Mar 20.

DOI:10.1016/j.clim.2023.109297

PMID:36940814

Abstract

Autoantibodies against NETs (ANETA) are present in SLE patients. We aimed to determine the clinical relevance of ANETA in SLE. Serum from 129 SLE patients, 161 patients with various rheumatoid diseases (DC), and 53 healthy controls (HC) were tested by a home-made ANETA ELISA platform. ANETA showed a sensitivity of 35.7% and a specificity of 92.5%, respectively, in the diagnosis of SLE. The combination of ANETA with anti-dsDNA antibody increased the diagnostic sensitivity from 49.6% to 62.8% for SLE. The presence of ANETA potentiates the clinical utility of anti-dsDNA antibodies in identifying a subset of SLE patients with higher disease activity and hematological abnormalities. The binding of ANETA to NETs did not inhibit the immunostimulatory effect of NETs. Our findings suggested that ANETA have potential as clinically relevant biomarkers that potentiate the clinical performance of anti-dsDNA antibodies in the diagnosis, risk stratification and subtyping of patients with SLE.

摘要

抗 NET 自身抗体 (ANETA) 存在于 SLE 患者中。我们旨在确定 ANETA 在 SLE 中的临床相关性。使用自制的 ANETA ELISA 平台检测了 129 例 SLE 患者、161 例各种类风湿疾病 (DC) 患者和 53 名健康对照者 (HC) 的血清。ANETA 在 SLE 的诊断中具有 35.7%的灵敏度和 92.5%的特异性。ANETA 与抗 dsDNA 抗体的组合将 SLE 的诊断灵敏度从 49.6%提高到 62.8%。ANETA 的存在增强了抗 dsDNA 抗体在识别具有更高疾病活动度和血液学异常的 SLE 患者亚群中的临床实用性。ANETA 与 NETs 的结合并不抑制 NETs 的免疫刺激作用。我们的研究结果表明，ANETA 具有作为临床相关生物标志物的潜力，可增强抗 dsDNA 抗体在 SLE 患者的诊断、风险分层和亚型中的临床性能。